Bayer Aktiengesellschaft (BAYZF)
OTCMKTS · Delayed Price · Currency is USD
31.71
0.00 (0.00%)
Jul 16, 2025, 9:30 AM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Crop Science | 22.26B | Log In | Log In | Log In | Log In | Upgrade |
Crop Science Growth | -3.92% | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceuticals | 18.13B | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceuticals Growth | 1.60% | Log In | Log In | Log In | Log In | Upgrade |
Consumer Health | 5.87B | Log In | Log In | Log In | Log In | Upgrade |
Consumer Health Growth | 0.87% | Log In | Log In | Log In | Log In | Upgrade |
Enabling Functions and Consolidation | 19.00M | Log In | Log In | Log In | Log In | Upgrade |
Enabling Functions and Consolidation Growth | - | Log In | Log In | Log In | Log In | Upgrade |
All Other Segment | 327.00M | Log In | Log In | Log In | Log In | Upgrade |
All Other Segment Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Crop Science Adjusted EBITDA | 4.33B | Log In | Log In | Log In | Log In | Upgrade |
Crop Science Adjusted EBITDA Growth | -12.71% | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceuticals Adjusted EBITDA | 4.72B | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceuticals Adjusted EBITDA Growth | -7.71% | Log In | Log In | Log In | Log In | Upgrade |
Consumer Health Adjusted EBITDA | 1.37B | Log In | Log In | Log In | Log In | Upgrade |
Consumer Health Adjusted EBITDA Growth | 1.03% | Log In | Log In | Log In | Log In | Upgrade |
Enabling Functions and Consolidation Adjusted EBITDA | -352.00M | Log In | Log In | Log In | Log In | Upgrade |
Enabling Functions and Consolidation Adjusted EBITDA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
All Other Segment Adjusted EBITDA | 62.00M | Log In | Log In | Log In | Log In | Upgrade |
All Other Segment Adjusted EBITDA Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Europe/Middle East/Africa | 13.98B | Log In | Log In | Log In | Log In | Upgrade |
Europe/Middle East/Africa Growth | -0.32% | Log In | Log In | Log In | Log In | Upgrade |
North America | 16.48B | Log In | Log In | Log In | Log In | Upgrade |
North America Growth | 2.68% | Log In | Log In | Log In | Log In | Upgrade |
Asia/Pacific | 8.07B | Log In | Log In | Log In | Log In | Upgrade |
Asia/Pacific Growth | 1.65% | Log In | Log In | Log In | Log In | Upgrade |
Latin America | 8.08B | Log In | Log In | Log In | Log In | Upgrade |
Latin America Growth | -10.76% | Log In | Log In | Log In | Log In | Upgrade |